Skip to main content
MedicHelpLine
Join Free
Verified Professional Network190+ CountriesHIPAA-Aware Platform
Back to Drug Index
General MedicationsTOPICALGeneric

XEGLYZE

ABAMETAPIR

Standard Dose
0.74%
Max Dose
Refer to approved labeling
Primary Use
Review priority: STANDARD Marketing status: Discontinued
Summary

Approval overview XEGLYZE is listed in Drugs@FDA under application 206966 (NDA).

Review priority: STANDARD Marketing status: Discontinued Active ingredient ABAMETAPIR Form and strength LOTION;TOPICAL - 0.74% Sponsor HATCHTECH Submission history Latest submission status date: 2022-07-20 00:00:00.

Structured Monograph

Clinical summary

Approval overview XEGLYZE is listed in Drugs@FDA under application 206966 (NDA). Review priority: STANDARD Marketing status: Discontinued Active ingredient ABAMETAPIR Form and strength LOTION;TOPICAL - 0.74% Sponsor HATCHTECH Submission history Latest submission status date: 2022-07-20 00:00:00. Submission type: SUPPL.

Monitoring

  • • Marketing status: Discontinued
  • • Review priority: STANDARD

Interaction Notes

  • No interaction notes stored yet.